Profile : 비체담 a specialized biotech company

ABOUT US>Profile

Company profile

Discover BICHEDAM’s Core Values,
Technology & Business Strategy.

BICHEDAM’s Oral Puerarin Breakthrough:
A New Paradigm for Vascular Disease

BICHEDAM has successfully developed an oral formulation of Puerarin by improving its bioavailability,
advancing oral treatment for degenerative vascular diseases.

With BCD101, a Phase 1-completed asset, and the launch of “G Care for Everyone,”
BICHEDAM is validating early market response and generating initial revenue.

Bichedam is

BICHEDAM is a biopharmaceutical company developing mechanism-based therapeutics that directly target the pathophysiological causes of disease, leveraging its formulation optimization platform for poorly soluble drugs.
Going beyond the limitations of conventional treatments focused on short-term symptom relief, BICHEDAM aims to create an innovative treatment environment that enables patients to safely take therapies over the long term.

At Bichedam

BICHEDAM’s core pipeline targets a broad range of challenging age-related diseases, starting with Nocturnal Leg Cramps (NLC) and expanding to Mild Cognitive Impairment (MCI) and Isolated Systolic Hypertension (ISH). Through global licensing and co-development partnerships with multinational pharmaceutical companies, BICHEDAM aims to become a leading global drug development company.

BICHEDAM aims to provide safe, essential chronic disease solutions for an aging population, driven by innovative drug delivery technologies and multi-target mechanisms of action.

Our ultimate goal is to develop a first-in-class therapy that fundamentally alleviates vascular and muscle stiffness by transforming conventional injectable treatments—limited by co-solvent toxicity and hospital-based administration—into convenient, self-administered oral therapies for everyday use.

Proprietary oral formulation technology overcoming the limited bioavailability of the key active ingredient, Puerarin
Development of a RhoA/ROCK-targeted therapy for Nocturnal Leg Cramps (NLC), addressing unmet medical needs
Expansion into a broad range of degenerative vascular and neurological diseases, including Mild Cognitive Impairment (MCI) and Isolated Systolic Hypertension (ISH)

uccessfully completed Phase 1 clinical trials for the lead candidate BCD101, demonstrating favorable safety, tolerability, and PK profiles
Phase 2 clinical trials for Nocturnal Leg Cramps (NLC) underway in collaboration with leading hospitals, including Seoul St. Mary’s Hospital and Uijeongbu St. Mary’s Hospital
Licensing partnerships in progress with leading global and Korean pharmaceutical companies through CDA/NDA agreements

Key Pipeline

	Code	Indications	Description
Innovative Medicines	BCD101	Noturnal leg cramps Rho-kinase inhibitor	'25 Completion of Phase 1 clinical trial in Korea
	BCD102	ISH Combination Therapy Rho-kinase inhibitor	'26 Clinical IND submission and global technology transfer
	BCD103	AD(Dementia) Rho-kinase inhibitor	'26 Clinical IND submission and global technology transfer
	BCD201	Non-Alcoholic Steatohepatitis Rho-kinase inhibitor	Preparing for nonclinical trials
	BCD202	Primary Biliary Cirrhosis Rho-kinase inhibitor	Preparing for nonclinical trials

	Code	Indications	Description
Health Supplements	BCD300	Women's Menopause	Technology Transfer to Helixmith Co., Ltd. Completed
	BCD301	Blood Circulation Health	Launching '25
	BCD302	River Health	Launching '26

Innovative Medicines

Health Supplements

Development Need

Ⅰ. NLC is common, affecting approximately 40% of adults aged 40 and older, with a high prevalence in the elderly population.

Ⅱ. Blood circulation disorders and cognitive decline frequently occur in patients with chronic diseases,
necessitating the development of products to improve these conditions.

Ⅲ. Nhere are no approved specialized treatments for NCL,
and existing therapeutic approaches have limited efficacy or are difficult to use long-term.

Differentiation

Solution Expansion

Based on the prospective observational study and safety validation conducted, expansion into an integrated solution for vascular health and leg cramps

Korean Medicine-Based

Currently, there are no Korean medicine-based treatments in NLC therapy. This multi-mechanism treatment simultaneously targets vascular relaxation, muscle tension relief, and improved sleep quality through a herbal compound prescription.

Core Targeting

It enables integrated management of blood circulation and lower limb cramps in the core patient group aged 50-70.

Results of Previous Research

Status of Previous Research

01. Clinical Observational Studies

02. Safety Verification

03. New Drug Development Stages

BCD101: 30 Hypertensive Patients

Prospective Observational Study Completed

01. Clinical Observational Studies

BCD101 Completes Prospective Observational Study in 30 Hypertensive Patients

Blood Pressure Improvement Effects and Safety Verified

Through Korea Institute of Oriental Medicine

02. Safety Verification

Blood Pressure Improvement Effects and Safety Verified Through Korea Institute of Oriental Medicine

Enters Rapid New Drug Development Phase

Based on Clinical Evidence

03. New Drug Development Stages

Enters Rapid New Drug Development Phase Based on Clinical Evidence

Research team

BICHEDAM Co., Ltd.

Head Office
Room 321, Korea Institute of Industrial Technology Research Center,
280 Daehak-ro, Gyeongsan-si, Gyeongsangbuk-do, Korea

Branch Office
Room 1516, Sky Valley 5th Building, 416 Hwagok-ro, Gangseo-gu, Seoul, Korea

CEO Hobin Moon

Email admin@bichedam.org